Studies how new drugs work for adults with acute myeloid leukemia in routine care
Observes how new drugs, alone or combined, perform in adults with acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
Key facts
- Where
- San Giovanni Rotondo and Sassari, ItalySee the 2 sites
Where in Italy
- Ematologia Ente Ecclesiastico Casa Sollievo Della SofferenzaSan Giovanni Rotondo, ItalyTaking people
- UOC Ematologia AOU di SASSARISassari, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Trial code
- NCT06513273
- Record updated
- 13 August 2025
- Original description
This multicenter, prospective and retrospective observational study aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult AML patients.Read full original descriptionShow less
Observational GIMEMA Study on the Outcome of Acute Myeloid Leukemia (AML) Patients Treated With New Drugs in Real-life
This multicenter, prospective and retrospective observational study aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult AML patients.
Inclusion: Aged 18 years or older; AML diagnosis according to the ELN guidelines, excluding M3; Signed Informed consent, if applicable; Treatment initiation with novel drugs in monotherapy or combination, in accordance with the AIFA authorizations, from the AIFA registration up to 31.12.2027 with particular attention to:; patients affected by FLT3-mutated AML treated with gilteritinib; patients affected by IDH-mutated AML treated with IDH inhibitors; patients affected by AML in maintenance therapy with oral azacytidine; patients affected by AML treated with glasdegib; patients affected by AML treated with gemtuzumab ozogamicin; other novel drugs or combination for the treatment of AML approved during the study period.
Exclusion: Patients included in interventional clinical trials.